Inflammatory bowel disease (IBD) is a complex disease involving various cells and signaling pathways during onset and progression.
To control the complexity of IBD integratively, we breaked away from the traditional method of strongly inhibiting one pathway.
We analyzed various signaling pathways related to IBD, identified a novel target involved in most of the pathways, and discovered inhibitors for the target. Based on the clear efficacy of inhibitors, we are developing the first-in-class drug for IBD.